Show simple item record

dc.contributor.authorTruelove, M.
dc.contributor.authorPatel, A.
dc.contributor.authorBompoint, S.
dc.contributor.authorBrown, A.
dc.contributor.authorCass, A.
dc.contributor.authorHillis, G.
dc.contributor.authorPeiris, D.
dc.contributor.authorRafter, N.
dc.contributor.authorReid, Christopher
dc.contributor.authorRodgers, A.
dc.contributor.authorTonkin, A.
dc.contributor.authorUsherwood, T.
dc.contributor.authorWebster, R.
dc.contributor.authorKanyini GAP Collaboration
dc.identifier.citationTruelove, M. and Patel, A. and Bompoint, S. and Brown, A. and Cass, A. and Hillis, G. and Peiris, D. et al. 2015. The Effect of a Cardiovascular Polypill Strategy on Pill Burden. Cardiovascular Therapeutics. 33 (6): pp. 347-352.

AIMS: Recent trials of cardiovascular polypills in high-risk populations show improvements in use of cardiovascular preventive treatments, compared to usual care. We describe patterns of pill burden in Australian practice, define the impact of polypill therapy on pill burden and explore how physicians add medication to polypill therapy. METHODS: The Kanyini Guidelines Adherence with the Polypill study was an open-label trial involving 623 participants in Australia which randomised participants to a polypill strategy (containing a statin, anti-platelet agent and 2 blood pressure lowering medications) or usual care. Participants either had established cardiovascular disease or were at high calculated risk (= 15% over 5 years). Current medications, daily pill burden, and self-reported use of combination treatment were recorded prior to randomisation and at study end. Median pill burden at baseline and study end were compared in both arms. Subgroup analysis of the polypill strategy on trial primary outcomes was conducted by pill burden at baseline. RESULTS: Median total and cardiovascular pill burdens of the polypill group decreased from 7 to 5 and from 4 to 2 respectively (median change -2; IQR -3, 0) with no change in the usual care group (comparison of change; p<0.001). No change was seen for non-cardiovascular medications. Of those still using the polypill at study end, 43.8% were prescribed additional medications; 84.5% of these additional medications were blood pressure lowering medications. Within the polypill group, lower pill burden at baseline was associated with greater increases in the use of indicated cardiovascular preventive medications at study end compared to those with higher pill burdens. No trend was observed between the level of baseline pill burden and the effect of poylpill treatment on systolic blood pressure or total cholesterol. CONCLUSION: A cardiovascular polypill in contemporary Australian practice reduces cardiovascular and total pill burdens, despite frequent prescription of additional medications. This article is protected by copyright. All rights reserved.

dc.titleThe Effect of a Cardiovascular Polypill Strategy on Pill Burden.
dc.typeJournal Article
dcterms.source.titleCardiovasc Ther
curtin.departmentDepartment of Health Policy and Management
curtin.accessStatusOpen access via publisher

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record